The severe cardiorenal syndrome: 'Guyton revisited'

European Heart Journal

Volumn 26, Issue 1, 2005, Pages 11-17

  Bongartz, Lennart G ^a   Cramer, Maarten Jan ^a   Doevendans, Pieter A ^a   Joles, Jaap A ^b   Braam, Branko ^b  

^a Heart Lung Institute Utrecht   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiorenal connection; Heart failure; Renal function; Severe cardiorenal syndrome

Indexed keywords

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMORBIDITY; DISEASE COURSE; EXTRACELLULAR SPACE; HEART DISEASE; HEART FAILURE; HEART OUTPUT; HEMODYNAMICS; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEVERE CARDIORENAL SYNDROME;

BLOOD PRESSURE; CORONARY ARTERIOSCLEROSIS; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHRITIS; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SYNDROME;

EID: 13544261698     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi020     Document Type: Review

References (110)

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 1997 Annual Data Report. Bethesda, MD, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1997. http:// www.usrds.org/adr_1997.htm (11 November 2003).
2. Raine AE, Margreiter R, Brunner FP et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992;7(Suppl. 2):7-35.
3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl. 12):S16-S23.
4. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
5. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002;17(Suppl. 11):50-54.
6. Muntner P, He J, Hamm L et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-753.
7. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002;62:1402-1407.
8. Beddhu S, Allen-Brady K, Cheung AK et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002;62:1776-1783.
9. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003;41:1364-1372.
10. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.
11. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
12. Al Suwaidi J, Reddan DN, Williams K et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974-980.
13. Best PJ, Lennon R, Ting HH et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.
14. Rao V, Weisel RD, Buth KJ et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation 1997;96(Suppl.): II-38-43; discussion II-44-45.
15. Gibson CM, Pinto DS, Murphy SA et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535-1543.
16. Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002;137:563-570.
17. Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003;24:412-420.
18. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 1998 Annual Data Report. Bethesda, MD, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998. http:// www.usrds.org/adr_1998.htm (20 January 2004).
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1-S266.
20. McCullough PA, Philbin EF, Spertus JA et at. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-69.
21. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987;31:1402-1415.
22. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-1009.
23. Guyton AC. The surprising kidney-fluid mechanism for pressure control-its infinite gain! Hypertension 1990;16:725-730.
24. Dorhout Mees EJ. Cardiovascular Aspects of Dialysis Treatment: The Importance of Volume Control. Dordrecht/Boston/London: Kluwer Academic Publishers, 2000.
25. Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection. Hypertension 2004;43:e14.
26. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
27. Clyne N, Lins LE, Pehrsson SK. Occurrence and significance of heart disease in uraemia. An autopsy study. Scand J Urol Nephrol 1986;20:307-311.
28. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002;106:100-105.
29. Rambausek M, Ritz E, Mall G et al. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985;28:775-782.
30. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996;50:1321-1326.
31. Tornig J, Gross ML, Simonaviciene A et al. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol 1999;10:77-83.
32. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-1022.
33. Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 2003;41:1253-1258.
34. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004;43:163-168.
35. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-223.
36. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
37. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
38. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585.
39. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-272.
40. Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996;5:89-96.
41. Warren DJ, Ferris TF. Renin secretion in renal hypertension. Lancet 1970;1:159-162.
42. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
43. Ushio-Fukai M, Zafari AM, Fukui T et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317-23321.
44. Chabrashvili T, Kitiyakara C, Blau J et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003;285:R117-R124.
45. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003;35:851-859.
46. Heymes C, Bendall JK, Ratajczak P et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003;41:2164-2171.
47. Tojo A, Onozato ML, Kobayashi N et al. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002;40:834-839.
48. Hornig B, Landmesser U, Kohler C et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805.
49. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 2000;57:2285-2298.
50. Pueyo ME, Gonzalez W, Nicoletti A et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-651.
51. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992;262:E763-E778.
52. Converse RL Jr, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.
53. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-1328.
54. Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003;14:425-430.
55. Zhang W, Huang BS, Leenen FH. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am J Physiol 1999;276:H1608-H1615.
56. Braam B. Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume. Am J Physiol 1999;276(Pt2):R1551-R1561.
57. Zou AP, Li N, Cowley AW Jr. Production and actions of superoxide in the renal medulla. Hypertension 2001;37:547-553.
58. Welch WJ, Wilcox CS. AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 2001;59:1257-1263.
59. Ren Y, Carretero OA, Garvin JL. Mechanism by which superoxide potentiates tubuloglomerular feedback. Hypertension 2002; 39:624-628.
60. Ortiz PA, Garvin JL. Interaction of O(2)(-) and NO in the thick ascending limb. Hypertension 2002;39:591-596.
61. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59:1960-1966.
62. Maggi E, Bellazzi R, Gazo A et al. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
63. Ha TK, Sattar N, Talwar D et al. Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJMed 1996;89:765-769.
64. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
65. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996;148:291-300.
66. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cordiol 1997;29:856-861.
67. Kielstein JT, Bode-Boger SM, Klein G et al. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 2003;33:370-375.
68. Lin HH, Chen CH, Hsieh WK et al. Hydrogen peroxide increases the activity of rat sympathetic preganglionic neurons in vivo and in vitro. Neuroscience 2003;121:641-647.
69. Shokoji T, Nishiyama A, Fujisawa Y et al. Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension 2003;41:266-273.
70. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ('carbonyl stress'). Kidney Int Suppl 2001;78:S25-S31.
71. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
72. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997;12:255-258.
73. Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-2532.
74. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V et ai. Oxidized low-density lipoprotein induces macrophage respiratory burst via its protein moiety: A novel pathway in atherogenesis? Biochem Biophys Res Commun 1999;263:804-809.
75. Herbst U, Toborek M, Kaiser S et al. 4-Hydroxynonenal induces dysfunction and apoptosis of cultured endothelial cells. J Cell Physiol 1999;181:295-303.
76. Katoh M, Egashira K, Usui M et al. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998;83:743-751.
77. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
78. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-1218.
79. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407-414.
80. Zebrack JS, Anderson JL, Beddhu S et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003;42:57-63.
81. Zoccali C, Benedetto FA, Mallamaci F et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000;18:1207-1213.
82. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133-139.
83. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
84. Levine B, Kalman J, Mayer L et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
85. Torre-Amione G, Kapadia S, Benedict C et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
86. Woldbaek PR, Tonnessen T, Henriksen UL et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res 2003;59:122-131.
87. Ward RA, McLeish KR. Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 1995;5:1697-1702.
88. Wassmann S, Stumpf M, Strehlow K et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004;94:534-541.
89. Sanchez-Lozada LG, Tapia E, Johnson RJ et al. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl 2003;64(Suppl. 86):S9-S14.
90. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002;55:329-340.
91. Ono K, Matsumori A, Shioi T et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998;98:149-156.
92. Niijima A, Hori T, Aou S, Oomura Y. The effects of interleukin-1 beta on the activity of adrenal, splenic and renal sympathetic nerves in the rat. J Auton Nerv Syst 1991;36:183-192.
93. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. Br Med J 2000;320:167-170.
94. Luo M, Hess MC, Fink GD et al. Differential alterations in sympathetic neurotransmission in mesenteric arteries and veins in DOCA-salt hypertensive rats. Auton Neurosci 2003;104:47-57.
95. Amin JK, Xiao L, Pimental DR et at. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001;33:131-139.
96. Leineweber K, Heinroth-Hoffmann I, Ponicke K et al. Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 2002;13:117-124.
97. Bristow MR, Ginsburg R, Minobe W et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-211.
98. Maurice JP, Shah AS, Kypson AP et al. Molecular beta-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol 1999;276:H1853-H1860.
99. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 1997;11(Suppl. 1):247-256.
100. Wikstrand J, Berglund G, Hedblad B, Hulthe J. Antiatherosclerotic effects of beta-blockers. Am J Cardiol 2003;91:25H-29H.
101. Erami C, Zhang H, Ho JG et al. Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002;283:H1577-H1587.
102. Bleeke T, Zhang H, Madamanchi N et al. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res 2004;94:37-45.
103. Bianchi P, Seguelas MH, Parini A, Cambon C. Activation of pro-apoptotic cascade by dopamine in renal epithelial cells is fully dependent on hydrogen peroxide generation by monoamine oxidases. J Am Soc Nephrol 2003;14:855-862.
104. Liao J, Keiser JA, Scales WE et al. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol 1995;268:R896-R901.
105. Oddis CV, Simmons RL, Hattler BG, Finkel MS. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am J Physiol 1995;269(Pt 2):H2044-H2050.
106. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-2109.
107. Li L, Lee EW, Ji H, Zukowska Z. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol 2003;23:1204-1210.
108. Schwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 1994;51:53-61.
109. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 1995;771:219-233.
110. Morris MJ, Cox HS, Lambert GW et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 1997;29:137-143.